F J Cummings

1.5k total citations
35 papers, 1.2k citations indexed

About

F J Cummings is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, F J Cummings has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 8 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in F J Cummings's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). F J Cummings is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). F J Cummings collaborates with scholars based in United States and South Africa. F J Cummings's co-authors include D C Tormey, Geoffrey Falkson, Rebecca Gelman, Peter A. Calabresi, Arvin S. Glicksman, Susan Masterson‐Allen, Vincent Mor, Marsha D. Fretwell, Leo L. Stolbach and Richard J. Goldberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

F J Cummings

35 papers receiving 1.1k citations

Peers

F J Cummings

ONCOL

IMMUN

PFM

PRM

Maureen Ross United States

J J Costanzi United States

Ellen R. Gaynor United States

Oliver Glidewell United States

Jacques Camerlo France

Daniel Vorobiof South Africa

Monica Giordano Italy

Roberta Camisa Italy

Jeffrey Margolis United States

Catherine Shannon Australia

Maureen Ross United States

F J Cummings

1.0k ×1.5

ONCOL

426 ×1.4

182 ×0.7

IMMUN

233 ×1.1

PFM

288 ×1.8

PRM

Citations per year, relative to F J Cummings F J Cummings (= 1×) peers Maureen Ross

Countries citing papers authored by F J Cummings

Since Specialization

Citations

This map shows the geographic impact of F J Cummings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F J Cummings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F J Cummings more than expected).

Fields of papers citing papers by F J Cummings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F J Cummings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F J Cummings. The network helps show where F J Cummings may publish in the future.

Co-authorship network of co-authors of F J Cummings

This figure shows the co-authorship network connecting the top 25 collaborators of F J Cummings. A scholar is included among the top collaborators of F J Cummings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F J Cummings. F J Cummings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lum, Lawrence G., Archana Thakur, Zaid Al‐Kadhimi, et al.. (2015). Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clinical Cancer Research. 21(10). 2305–2314. 87 indexed citations

Fournier, John, et al.. (2014). Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. Dermatology Online Journal. 20(10). 7 indexed citations

Cummings, F J. (2002). Evolving uses of hormonal agents for breast cancer therapy. Clinical Therapeutics. 24. C3–C25. 20 indexed citations

Falkson, Geoffrey, Rebecca Gelman, K. J. Pandya, et al.. (1998). Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.. Journal of Clinical Oncology. 16(5). 1669–1676. 66 indexed citations

Akerley, Wallace, et al.. (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.. PubMed. 24(5 Suppl 17). S17–90. 28 indexed citations

Falkson, Geoffrey, Christina Holcroft, Rebecca Gelman, et al.. (1995). Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.. Journal of Clinical Oncology. 13(6). 1453–1458. 47 indexed citations

Cummings, F J, Ki Wook Kim, Richard S. Neiman, et al.. (1991). Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.. Journal of Clinical Oncology. 9(4). 565–571. 71 indexed citations

Cassileth, Peter A., Brigitte Cheuvart, A. S. D. Spiers, et al.. (1991). Pentostatin induces durable remissions in hairy cell leukemia.. Journal of Clinical Oncology. 9(2). 243–246. 83 indexed citations

Posner, Marshall R., Peter A. Calabresi, I. Brunetti, et al.. (1990). Oral Zidovudine, Continuous-Infusion Fluorouracil, and Oral Leucovorin Calcium: A Phase I Study. JNCI Journal of the National Cancer Institute. 82(21). 1710–1714. 20 indexed citations

10.

Taylor, S G, Matthew Knuiman, Lynn A. Sleeper, et al.. (1989). Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.. Journal of Clinical Oncology. 7(7). 879–889. 44 indexed citations

11.

Cummings, F J, Gerald W. Crabtree, Michael C. Wiemann, et al.. (1988). Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin. Clinical Pharmacology & Therapeutics. 44(5). 501–509. 7 indexed citations

12.

Mor, Vincent, Edward Guadagnoli, Susan Masterson‐Allen, et al.. (1988). The Brown University Cancer and Aging Study: a statewide cooperative investigation. Study provides insights into the appropriate management of cancer in the elderly.. PubMed. 71(10). 379–86. 3 indexed citations

13.

Posner, Marshall R., L. Ferrari, F J Cummings, et al.. (1987). A phase I trial of continuous infusion cisplatin. Cancer. 59(1). 15–18. 36 indexed citations

14.

Cummings, F J, Rebecca Gelman, & John L. Horton. (1985). Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.. Journal of Clinical Oncology. 3(7). 932–940. 59 indexed citations

15.

Calabresi, Peter A., et al.. (1981). Mono clonal antibody production in artificial capillary cultures. 22. 302. 3 indexed citations

16.

Edmonson, J H, Stephen W. Lagakos, Leo L. Stolbach, et al.. (1976). Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 60(5). 625–7. 4 indexed citations

17.

Cummings, F J, Gloria H. Heppner, Paul Calabresi, Michael Byrne, & Leo L. Stolbach. (1975). Evaluation of cell‐mediated reactivity and serum blocking factors in melanoma patients on chemotherapy. Medical and Pediatric Oncology. 1(3). 195–206. 2 indexed citations

18.

Heppner, G. H., Emmanuelle Henry, Leo L. Stolbach, et al.. (1975). Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.. PubMed. 35(8). 1931–7. 55 indexed citations

19.

Byrne, Michael, G H Heppner, Leo L. Stolbach, et al.. (1973). Tumor immunity in melanoma patients as assessed by colony inhibition and microcytotoxicity methods: a preliminary report.. PubMed. 37. 3–8. 7 indexed citations

20.

Heppner, G. H., Leo L. Stolbach, Michael Byrne, et al.. (1973). Cell‐mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. International Journal of Cancer. 11(2). 245–260. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact